Artificial Intelligence – Page 227

Symphony IndustrialAI Appoints Barry Johnson President of Digital Manufacturing

August 12, 2021 Published by Roboticulized.com

Symphony Industrial AI announced today the appointment of Barry Johnson as president of Digital Manufacturing. The move supports Symphony IndustrialAI’s rapid growth and its expansion into enterprise AI solutions for plant operations, visibility, and performance. The announcement comes on the heels of two additional key hires for the Symphony IndustrialAI’s digital manufacturing division, Vice President of Products Prashant Jagarlapudi and Chief Revenue Officer Ron Posey.

Johnson is an experienced senior executive with more than 25 years of demonstrated success in the industrial software sector, driving revenue growth and improving business performance internationally. Johnson previously served in multiple executive roles at Rockwell Automation, including global vice president of software sales. Before Rockwell, Barry held numerous software roles at GE, driving growth organically and inorganically.

“Enterprise AI in industrial applications has reached an inflection point, and Barry and his team are on the leading edge,” said Symphony IndustrialAI Chief Executive Officer Dominic Gallello. “As a transformational change leader, Barry plays a key role in fueling growth through close work with sales, product management, engineering, and professional services teams. Prashant and Ron bring added power to our work in digital manufacturing and Enterprise AI.”

“With the launch of the EurekaAI industrial platform and Symphony IndustrialAI’s digital manufacturing solutions, we are working with leaders across industrial applications to make strides in enterprise AI adoption,” said Johnson. “2021 is a year of immense transformation as we lay the digital foundation for the success of tomorrow’s industrial and manufacturing champions. There’s no team better suited to accelerate this evolution than Symphony IndustrialAI.”

These appointments follow Symphony IndustrialAI’s introduction of the end-to-end Eureka AI platform for manufacturing and the acquisition of Savigent.

Technology Investments will Help Oncology Practices Succeed in Value-based Care

August 11, 2021 Published by Roboticulized.com

Community oncology practices are continuing to adapt to value-based reimbursement models as the Centers for Medicare and Medicaid Services (CMS) prepares to transition from the Oncology Care Model (OCM) to the Oncology Care First (OCF) model in 2022. While the full details of this transition are still pending, OCF is expected to include more practices than OCM – and may create similar challenges for oncologists and administrators when it comes to achieving financial performance.

Frost & Sullivan’s latest article, From OCM to OCF: Lessons Learned and What’s Next, recaps the key takeaways from a recent discussion among oncology practices that participated in OCM about preparing for the future of value-based care. Sponsored by Cardinal Health Specialty Solutions, the discussion highlighted the need for internal champions, data transparency, and additional staff to follow up with and triage patients who may be experiencing adverse events. Participating practice leaders also offered recommendations to community oncology practices that may be embarking on value-based reimbursement for the first time.

To download the complimentary white paper, please visit: http://frost.ly/62s

“When it comes to succeeding in value-based care, it is essential for oncology practices to have a champion in an administrative role. This will ensure that the practice has a person who sees the whole picture, speaks the clinical language, and drives the overall operational change,” observed Patrick Riley, Healthcare & Life Sciences, Industry Principal at Frost & Sullivan. “It is also vital to add or assign staff to regularly follow up with patients and proactively address health issues before they lead to an ER visit.”

“To make the best use of their staff and resources and ensure that patients receive optimal care, practices are increasingly reliant on predictive data and analytics,” noted Amy Valley, Vice President, Clinical Strategy at Cardinal Health Specialty Solutions. “Artificial intelligence-enabled technology can be used to deliver actionable insights to help identify patients at high risk of mortality, ER visits, and hospital readmission, and provide them with early interventions. Data transparency will not only improve patient outcomes but also help practices achieve their financial targets.”

Community oncology practices need to prepare for the transition to OCF in 2022. After evaluating their current data trends, costs and care outcomes, practices should consider the following steps for a successful transition to this next value-based payment model:

Be better prepared to take on more risks.
Establish a baseline metric from current performance periods and then adjust as needed to address areas of opportunity.
Invest in the resources and technology necessary to monitor and pivot to meet the demands of the evolving value-based care landscape.

aMind Joins Argano to Build Quote-to-Cash Solutions that Make Businesses Run Better

August 11, 2021 Published by Roboticulized.com

Argano announced today aMind Solutions will join its platform to build omni-channel enabled quote-to-cash solutions that are integral to the digital foundations that make businesses run better.

Headquartered in Alamo, California, go-to Salesforce partner aMind Solutions was founded in 2005 to deliver elegant, mission critical, high transaction throughput configure, price, quote (CPQ) and billing applications across sales, partners, field service and eCommerce channels. The company’s highly satisfied and 100 percent referenceable client base has been achieved by their laser focus on customer success.

“Quote to cash success requires aligning the breadth, depth and nuance of platform capabilities with core business processes while meeting expectations of a best-in-class customer experience,” said Billy Hunt, President of aMind Solutions. “We take our responsibility as frictionless quote to cash experts and our track record of success seriously, which is a key reason why the fit with Argano’s all-star results-oriented culture is excellent.”

Argano brings together specialized firms on an integrated platform. This model offers clients access to a unified set of unique business and technology solutions that are core to strong Digital Foundation including:

Enabling sales and services to deliver frictionless customer experiences that optimize revenue.
Architecting integrated logistics and supply chains that are resilient and flexible.
Delivering agile planning systems and analytics that drive a more strategic approach to financial management.
Implementing ERP systems and processes that improve data visibility and integrity across core operations.
Building workforce solutions that enhance employee engagement, productivity and value.

“aMind is a leader in quote-to-cash, successfully delivering multi-channel solutions that stay ahead of, and in fact define the future in a world challenged by accelerating complexity,” said Argano Group CEO, and former Co-CEO of PublicisSapient, Chip Register. “High-value solutions require a strong empirical approach to prioritizing features that deliver the greatest business benefit. aMind’s expertise deepens Argano’s ability to support complex businesses from commerce to cash to close.”

Five companies precede aMind Solutions in joining the Argano platform. SCMO2 is a leader in supply chain planning and transformation. Arbela Technologies brings expertise in ERP, CRM and analytics solutions. ArganoKeste is an award-winning technology services firm focused on commerce to cash solutions in the B2B space. ArganoInterRel brings unmatched experience in enterprise performance management (EPM) and business intelligence (BI) software. And, ArganoUV brings world-class design and technology talent to the platform, delivering ground-breaking commerce experiences for some of the world’s leading B2C brands.

Diabetes Devices Market Size Worth $44.6 Billion By 2028 | CAGR 6.6%: Grand View Research, Inc.

August 11, 2021 Published by Roboticulized.com

The global diabetes devices market size is expected to reach USD 44.6 billion by 2028, registering a CAGR of 6.6% over the forecast period, according to a new report by Grand View Research, Inc. The market is driven by factors such as increasing incidence of diabetes, technological advancements, and innovative product launches. Increasing adoption of advanced diabetes management solutions in developing region, government policies, and rising medical tourism are some of the major factors contributing to the market growth. Furthermore, rising government initiatives to spread awareness about diabetes and increasing R&D expenditure of major players are the factors expected to boost the market growth.

Key Insights & Findings:

North America accounted for the largest share in 2019, in terms of revenue, owing to favorable reimbursement policies, presence of key players, and frequent product launches
By product, the insulin delivery devices segment accounted for the largest market share and is also expected to grow at the fastest rate
In the Blood Glucose Monitoring (BGM) segment, self-monitoring devices dominated the market owing to their low cost and high usage
In Self-monitoring of Blood Glucose (SMBG) devices, testing strips segment dominated the market while blood glucose meters are expected to grow at a significant pace owing to high adoption and technological advancements
In the Continuous Glucose Monitoring (CGM) devices segment, transmitters accounted for the largest share owing to high cost of devices and high usage
In insulin delivery devices, pens segment dominated the market since it is easy to carry, easy to use, and has low cost as compared to other delivery devices
By distribution channel, hospital pharmacy segment dominated the market owing to rise in sales of diabetes devices in these pharmacies
By end use, hospital segment accounted for the largest market share owing to improving healthcare infrastructure due to rising investment
The leading players present in the diabetes devices market are Medtronic plc; Abbott Laboratories; F.Hoffmann-La-Ltd; Bayer AG; Lifescan, Inc.; B Braun Melsungen AG; Lifescan, Inc.; Dexcom Inc.; Insulet Corporation; Ypsomed Holdings; Companion Medical; Sanofi; Valeritas Holding Inc.; Novo Nordisk; Arkray, Inc.; among others

Read 140 page market research report, “Diabetes Devices Market Size, Share & Trends Analysis Report By Type (BGM Devices, Insulin Delivery Devices), By Distribution Channel, By End-use (Hospitals, Homecare), By Region, And Segment Forecasts, 2021 – 2028“, by Grand View Research

According to a study published on National Center for Biotechnology Information (NCBI), global health expenditure on diabetes is expected to reach USD 490 billion in 2030 from 376 billion in 2010. Obesity, sedentary lifestyle, and fast food culture are some of the factors expected to have significant impact on the market growth. According to Harvard T.H. Chan School of Public Health, U.S. has the highest rates of obesity and it is expected to increase up to 50% by 2030.

In addition, increasing number of new market players, who focus on patient convenience with the help of artificial intelligence technology, are also transforming the market. They are leveraging technological advancements to improve diabetes care solutions like CGM devices, non-invasive insulin delivery systems, and digital diabetes management platforms. For instance, in December 2017, Companion Medical Launched Inpen, its first smart insulin pen system in the U.S. It is the only FDA-approved device that can combine insulin injector pen with a smart app.

Grand View Research has segmented the global diabetes devices market on the basis of type, distribution channel, end-use, and region:

Diabetes Devices Type Outlook (Revenue, USD Million, 2016 – 2028)
- BGM Devices
  - Self-Monitoring Devices
    - Blood Glucose Meters
    - Testing Strips
    - Testing Strips
  - Continuous Glucose Monitoring Devices
    - Sensors
    - Transmitters
    - Receiver
- Insulin Delivery Devices
  - Pumps
  - Pens
  - Syringes
  - Jet Injectors
Diabetes Devices Distribution Channel Outlook (Revenue, USD Million, 2016 – 2028)
- Hospital pharmacies
- Retail Pharmacies
- Diabetes Clinics/Centers
- Online Pharmacies
- Others
Diabetes Devices End-use Outlook (Revenue, USD Million, 2016 – 2028)
- Hospital
- Homecare
- Diagnostic Centers
Diabetes Devices Regional Outlook (Revenue, USD Million, 2016 – 2028)
- North America
  - U.S.
  - Canada
- Europe
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Czech Republic
  - Poland
  - Switzerland
  - Turkey
- Asia Pacific
  - Japan
  - China
  - India
  - Australia
  - Vietnam
  - Philippines
  - Malaysia
  - Indonesia
  - Thailand
  - South Korea
- Latin America
  - Brazil
  - Mexico
  - Argentina
  - Colombia
  - Chile
- Middle East & Africa
  - South Africa
  - Saudi Arabia
  - UAE
  - Egypt
  - Oman

List of Key Players of Diabetes Devices Market

Medtronic plc
Abbott Laboratories
F.Hoffmann-La-Ltd.
Bayer AG
Lifescan, Inc.
B Braun Melsungen AG
Dexcom Inc.
Insulet Corporation
Ypsomed Holdings
Companion Medical
Sanofi
Valeritas Holding Inc.
Novo Nordisk
Arkray, Inc.

Check out more studies related to the Global Medical Devices Industry, conducted by Grand View Research:

Pessary Market – The global pessary market size is expected to reach USD 547.2 million by 2028, according to a new report by Grand View Research, Inc.
Exoskeleton Market – The global exoskeleton market size is expected to reach USD 953.1 million by 2028, according to a new report by Grand View Research, Inc
Microneedling Market – The global microneedling market size is expected to reach USD 992.49 million by 2028, registering a CAGR of 7.9% over the forecast period, according to a new report by Grand View Research, Inc.

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

BOC Group Advances The Lean Enterprise Architecture Experience With ADOIT 13.0

August 11, 2021 Published by Roboticulized.com

BOC Group today announced ADOIT 13.0, enhanced with features that elevate some of its essential capabilities and make them smarter and more helpful in everyday tasks. The latest release packs even more intelligence and practicality into ADOIT by streamlining the way users get acquainted with the tool, access key asset information, and keep up with the transformation of their architecture over time. Led by users’ feedback, ADOIT 13.0 incorporates improvements that bump up performance and further ease the daily usage of the tool.

“ADOIT 13.0 expands on the new Lean EA ADOIT experience and adds more flesh to it by allowing users to quickly deliver on their business outcome-driven architectures with easier tool handling, all-encompassing architecture insights, and remarkably flexible and well-connected EA ecosystem,” said Christoph Moser, ADOIT product manager.

“Relying on the voices of our customers, we’re excited to level up ADOIT yet again, and shape it in a way that makes our users’ experience more valuable and engaging – ultimately supporting them in achieving their transformation goals faster.”

A detailed insight into the latest release is available on the BOC Group website.

BOC Group encourages all interested parties to give ADOIT 13.0 a try with the free ADOIT:Community Edition and experience the recent improvements for themselves.

Voltaiq partners with Veniam to provide global solution for transferring electrified vehicle battery data

August 11, 2021 Published by Roboticulized.com

VOLTAIQ, the industry leader in Enterprise Battery Intelligence and VENIAM, the leading intelligent networking platform provider have signed a partnership agreement to transfer an order of magnitude more electrification data to the cloud. Using VENIAM’s Intelligent Networking Platform, VOLTAIQ will enable its customers to make the most out of all available networks such as 4G/5G, Wi-Fi, and V2X networks, thereby transferring larger battery data sets to power their cloud analytics.

Battery technology has developed rapidly in the last 10 years and demand for electric vehicles is at an all-time high with growth rates over 300% per year. To further drive adoption, battery range and health are among the most pressing concerns. VOLTAIQ has developed the market’s only fully–automated, purpose–built battery analytics solution capable of systematically gathering, analyzing, and translating vast quantities of battery data into actionable insights. The company’s intelligent software solution equips customers with a holistic understanding of their battery systems, allowing them to access real–time battery function and predict future performance and behavior accurately.

To solve the challenge of transferring the fast growing data volumes in a cost-effective way, VOLTAIQ will leverage VENIAM’s unique ability to transfer 10x more data at 50% – 80% lower cost per gigabyte. This includes utilizing millions of Wi-Fi hotspots for data offload automatically even when the vehicles are on the move. Vehicles powered by VOLTAIQ will also be able to use enterprise Wi-Fi networks for data offload and even communicate securely among each other using Veniam’s advanced vehicle-to-vehicle communication capabilities.

Tal Sholklapper, VOLTAIQ CEO, says: We are only working with the best technology partners and did extensive research to find a superior platform that ensures safe data transfer between the vehicle and the cloud. Our partnership with Veniam is a milestone for our customers in making high-fidelity battery data available in mass production by easing the biggest concern which is the cost and convenience of large data transfers.

João Barros, CEO Veniam adds: We are delighted that VOLTAIQ has decided to partner with Veniam and use our intelligent networking platform for massive data transfers to the Cloud. Today, we are already transferring terabytes of mobile data per month in the most economic way. Going forward, we look forward to supporting VOLTAIQ in enabling the best customer experience for the owners of battery-powered vehicles and shaping future mobility in a way that addresses the challenges of climate change.

Appriss, Inc. Announces Definitive Agreement to Sell Appriss Insights, LLC to Equifax, Inc. for $1.825 billion

August 10, 2021 Published by Roboticulized.com

Appriss, Inc., a pioneer in data and analytics solutions that mitigate risks, improve health, and save lives, backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”) and Insight Partners, announced today that it has entered into a definitive agreement to sell Appriss Insights, LLC, a wholly owned business unit, to Equifax, Inc. in an all cash transaction for $1.825 billion. Appriss Insights provides data and analytics solutions to government agencies and commercial enterprises to improve community and workplace safety, improve healthcare credentialing, enable more effective law enforcement investigations, and mitigate fraud and improper payments in government entitlement programs.

Appriss Insights’s differentiated capabilities are expected to further enhance Equifax’s fast growing and market-leading Workforce Solutions. The deal is subject to customary closing conditions.

“Appriss was founded over 25 years ago with a mission to leverage data and technology to protect crime victims and make communities safer. This purpose has fueled innovation in other important areas such as workplace risk and financial fraud, where we’ve continued to enhance safety and help ensure valuable tax dollars stay where they’re most needed,” said Krishnan Sastry, Appriss Inc.’s CEO. “Appriss Insights and Equifax share a common vision for how to drive better decisions using a combination of our data and insights. We are incredibly proud to have the talented Appriss Insights team join forces with Equifax and to realize a shared vision faster.”

Appriss Insights pioneered VINE®, the victim-safety solution that connects to county jails and state prisons to monitor the movement of offenders. VINE® uses custody status information to deliver over 25 million notifications annually to keep victims and survivors of crime safe. Appriss Insights has expanded its data capabilities to become a leading provider of risk and criminal justice intelligence solutions for government agencies and employers. Appriss Insights continues to expand its capabilities to strengthen pre-hire background screening and post-hire continuous monitoring, and to mitigate fraud in various government entitlement programs such as unemployment insurance.

“The sale of Appriss Insights is a validation of Appriss’s original mission of delivering critical, proprietary data and analytics to help customers make better decisions,” said James Pade, Partner and Managing Director at Clearlake. “With this divestiture, Appriss will continue to invest in its healthcare and retail platforms, and Clearlake looks forward to helping Appriss grow its leadership position across these key verticals.”

“The innovative Appriss team continues to leverage unique data networks, analytics, and technology to bring new and improved solutions to multiple markets,” said Deven Parekh, Appriss, Inc.’s Chairman of the Board and Managing Director at Insight Partners. “This has resulted in top and bottom-line growth for 26 consecutive years – every single year of the company’s existence. We’re excited to see what the Appriss Insights and Equifax teams will achieve together and look forward to Insight’s continued partnership with the broader Appriss business.”

Appriss, Inc.’s other business units will continue under the ownership of Clearlake and Insight Partners, focused on providing data and technology solutions to improve how healthcare is delivered, to mitigate fraud and risk, and to improve consumer experience at all touchpoints for omnichannel retailers.

Loyalty Management Market Size Worth $17.65 Billion By 2028: Grand View Research, Inc.

August 10, 2021 Published by Roboticulized.com

The global loyalty management market size is anticipated to reach USD 17.65 billion by 2028, registering a CAGR of 12.3% from 2021 to 2028, according to a new study conducted by Grand View Research, Inc. The loyalty programs enterprises are running aggressively as part of the marketing strategies to encourage customers to stick to the brand and prevent them from switching to another are expected to drive the growth of the market. Loyalty programs envisage rewarding customers in the form of cashback, rewards points, gift cards, and discounts, and others for their purchases. They help enterprises in retaining customers and subsequently play a vital role in strengthening the customer base and augmenting sales.

Key Insights & Findings:

The software segment dominated the market in 2020 in the overall market with a share of 50%
The cloud-based segment is expected to grow significantly over the forecast period as cloud-based deployment offers various benefits, such as cost-saving and agility
The large enterprise segment dominated the market in 2020 as large enterprises belonging to various industries and industry verticals emphasized launching loyalty programs as part of the efforts to retain customers
The growth of the Asia Pacific regional market can be attributed to the rapid economic development of emerging economies, such as India and China

Read 140 page market research report, “Loyalty Management Market Size, Share & Trends Analysis Report By Component, By Software, By Deployment, By Organization, By Vertical, By Region, And Segment Forecasts, 2021 – 2028“, by Grand View Research

The growing adoption of advanced solutions that can track consumer behavior and monitor customer scores, and subsequently help in enhancing customer engagement is expected to drive the growth of the market over the forecast period. As the competition among brands intensifies, brands are aggressively pursuing various strategies, including running loyalty programs, as part of the efforts to satisfy customers and prevent them from switching to other brands, thereby contributing to the growth of the market. Continued introduction of various digitalized payment options to enhance consumer experience also bodes well for the growth.

Cloud-based deployment of loyalty management programs is expected to gain traction over the forecast period. Cloud-based deployment helps organizations in better managing their expenses and saving on the costs incurred on having a dedicated IT infrastructure while ensuring agility. The cloud-based deployment also facilitates real-time tracking of customer queries, retention rates, and response rates. Storing customer data on the cloud for further analysis can potentially help organizations in building a comprehensive view of the overall customer base.

The retail and consumer goods segment dominated the market in 2020. Retailers and consumer goods brands often embark upon various efforts to improve brand loyalty and encourage repetitive purchases. Rewarding customers with loyalty rewards in the form of gifts, discounts, certificates, and reward points, particularly helps in enhancing customer relationships. Hence, retailers and consumer goods brands are aggressively adopting loyalty management software.

Retaining the existing customers while simultaneously acquiring new customers is of paramount importance for incumbents of various industries and industry verticals. Telecom operators particularly put a strong emphasis on building trust and affinity with their subscribers by enhancing value-based services. Incumbents of the IT and telecommunications industry particularly opt for loyalty management solutions to retain their customers. North America accounted for the largest share of the market in 2020. North America is home to developed economies, such as the U.S. and Canada, which are known for aggressive adoption of the latest and advanced technologies, such as Artificial Intelligence (AI), cloud computing, and data analytics. A strong and well-developed IT infrastructure deployed in the region also bodes well for aggressive adoption of advanced loyalty management solutions. Customers in North America typically favor free shipping, cashback, and discounts as loyalty rewards. People are widely using credit and debit cards in the stores highly adopted loyalty programs in this region. The customers favor monetary offerings such as free shipping, cashback, discounts in this region. Asia Pacific is expected to register the highest CAGR over the forecast period as retailers in the region are focusing aggressively on enhancing customer experience. China is particularly dominating the regional market.

Grand View Research has segmented the global loyalty management market based on component, software, deployment, organization, vertical, and region:

Loyalty Management Component Outlook (Revenue, USD Million, 2018 – 2028)
- Software
- Service
Loyalty Management Software Outlook (Revenue, USD Million, 2018 – 2028
- Channel Loyalty
- Customer Loyalty
- Customer Retention
Loyalty Management Deployment Outlook (Revenue, USD Million, 2018 – 2028)
- On-Premise
- Cloud
Loyalty Management Organization Type Outlook (Revenue, USD Million, 2018 – 2028)
- Small and Medium Enterprise
- Large Enterprise
Loyalty Management Vertical Outlook (Revenue, USD Million, 2018 – 2028)
- Transportation
- IT & Telecommunication
- BFSI
- Media & Entertainment
- Retail & Consumer Goods
- Hospitality
- Others
Loyalty Management Regional Outlook (Revenue, USD Million, 2018 – 2028)
- North America
  - U.S.
  - Canada
- Europe
  - U.K.
  - Germany
- Asia Pacific
  - China
  - Japan
  - India
- Latin America
  - Brazil
  - Mexico
- Middle East & Africa

List of Key Players of Loyalty Management Market

AIMIA
BREIRLEY+PARTNERS
Comarch
Fivestars
ICF Next
Lacek Group
Oracle Corporation
SAP SE

Check out mor studies related to the Global IT Services & Applications Industry, conducted by Grand View Research:

Machine Learning Market – The global machine learning market size was valued at USD 6.9 billion in 2018 and is anticipated to register a CAGR of 43.8% from 2019 to 2025. Emerging technologies such as artificial intelligence are changing the way industries and humans work.
Artificial Intelligence Market – The global artificial intelligence market size was valued at USD 62.35 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 40.2% from 2021 to 2028.
U.S. Customer Relationship Management Market – The U.S. Customer Relationship Management market size was valued at USD 25.8 billion in 2018 and is anticipated to register a CAGR of 14.0% from 2019 to 2025.

Chlorobenzene Market to Grow With Substantial Growth Rate in Coming Years Says P&S Intelligence

August 10, 2021 Published by Roboticulized.com

The burgeoning requirement for chlorobenzene in various industries such as high-performance polymers, pharmaceuticals, agrochemicals, and personal care, is fueling the worldwide demand for chlorobenzene. Because of this factor, the global chlorobenzene market is predicted to exhibit huge expansion during 2021–2030.

Get the Sample Copy of this Report at @ https://www.psmarketresearch.com/market-analysis/chlorobenzene-market/report-sample

The chlorobenzene market is divided into ortho dichlorobenzene, monochlorobenzene, and para dichlorobenzene, depending on type. Out of these, the paradichlorobenzene category is predicted to demonstrate the highest CAGR in the market during the forecast period. This is credited to the soaring usage of paradichlorobenzene in the production of polyphenylene sulphide and the booming production of paradichlorobenzene in the U.S., Japan, and China.

Geographically, the Asia-Pacific (APAC) region held the largest share in the chlorobenzene market in 2020, and this trend is predicted to continue in the forthcoming years. This will be because of the soaring requirement for chlorobenzene in Japan and China. Currently, China is the largest consumer and producer of chlorobenzene in the world. Additionally, the production of polyphenylene sulphide resin is surging sharply in Japan, thereby propelling the market expansion in the APAC region.

Explore detailed report @ Chlorobenzene Market Research Report: By Type (Monochlorobenzene, Orthodichlorobenzene, Paradichlorobenzene), Application (Nitrochlorobenzene, Polysulfone, Polymer, Solvent), Industry (Agriculture, Textile, Pharmaceutical, Chemical, Paint & Coating, Cosmetic & Personal Care) – Global Industry Analysis and Growth Forecast to 2030

Due to the COVID-19 pandemic, the governments of many countries imposed lockdowns and strict social distancing regulations and also closed down borders, as these measures break the chain of transmission of the infection, thereby mitigating the spread of the disease. These measures massively hampered supply chain and logistics operations. As chlorobenzene is used as a chemical precursor or a solvent in the production of many products such as cosmetics, adhesives, paints, medicines, dyes, and polishes, the halt in industrial production caused a massive decline in its demand, thereby affecting the growth of the chlorobenzene market.

The players operating in the chlorobenzene market are focusing on collaborations to expand their operations geographically. For example, CHEMADA Industries Ltd., which is a producer of fine chemicals for numerous industries, announced in February 2020 that it has signed a distribution agreement with Moriroku Holdings Company Ltd. (Moriruko Japan), a company based in Japan. As per the agreement, Moriroku Japan was granted the rights to distribute the products of CHEMADA Industries in Japan.

Some of the major players in the global chlorobenzene market are Jiangsu Yangnong Chemicals Group Co. Ltd., Meryer (Shanghai) Chemical Technology Co. Ltd., Kureha Corporation, China Petrochemical Corporation, J&K Scientific Ltd., Beckmann-Kenko GmbH, and Applichem GmbH.

Global In-Vitro Diagnostics Market Size to Reach USD 118.44 Billion in 2028 | Increased Investment in Research & Development in Molecular Diagnostics and Development of New Product is Driving the Industry Demand, says Emergen Research

August 10, 2021 Published by Roboticulized.com

The global in-vitro diagnostics market size is expected to reach USD 118.44 Billion at a steady revenue CAGR of 4.4% in 2028, according to latest analysis by Emergen Research. In-vitro diagnostics market revenue growth is due to increased investment in research & development in genomics and proteomics industry.

Surge in geriatric population, prevalence of sedentary lifestyle that result in chronic diseases and rise in infectious diseases is driving the growth of the market. Increase in prevalence of target diseases such as gastrointestinal diseases, diabetes, cardiac disorders, cancer, and infectious diseases is contributing to in-vitro diagnostic market growth positively.

Rising incidence of surgical procedures is expected to fuel market growth. Increased awareness about personalized medicine and adoption of point-of-care testing is also contributing to in-vitro diagnostics market growth. However, strict regulatory framework and inadequate reimbursement policy will impede market growth. Moreover, shortage of skilled professionals to perform diagnostic tests effectively and lack of training programs are also hampering adoption of in-vitro diagnostics products.

Download FREE Sample Brochure (Customized Sample PDF File delivered as per your specific requirement)@ https://www.emergenresearch.com/request-sample/70

Advancement in technology has led to increased availability of over-the-counter tests for better treatment. It adds significant value to medical diagnosis and treatment processes, thus improving the well-being of the public. Another factor driving the market growth is development of next generation sequencing (NGS). NGS along with data analysis algorithm allow researchers and clinicians to uncover cancer pathways, hidden aspects of antibiotic resistance, and rare chronic diseases. It offers speed and accuracy and reduces time to diagnose.

Key players in the in-vitro diagnostics market include

Siemens Healthineers, Roche Diagnostics, Danaher Corporation, bioMérieux, Abbott Laboratories, DiaSorin, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, QIAGEN, and Sysmex Corporation.

Some Key Highlights in the Report

In July 2021, Ortho Clinical Diagnostics launched Interleukin-6 (IL-6) reagent pack, the latest addition to ortho’s critical care blood testing menu. Ortho is one of the world’s leading in-vitro diagnostic company and is available in the EU countries and several LATAM and APAC countries. The test is used to detect and evaluate inflammatory diseases, including auto-immune disorders, sepsis and severe respiratory infections from COVID-19.
Reagent segment accounted for largest revenue share in 2020. These kits and reagents are first line testing devices for at-home consumer-friendly glucose monitoring and pregnancy tests to more complex automated laboratory-based systems. Increase in production of rapid, sensitive devices which offers accurate results is also driving revenue growth of the segment.
Oncology segment revenue is forecasted to grow at the highest rate during the forecast period due to increasing rates of mortality and morbidity. Increased research activities and high level of funding from governments worldwide to develop solution for prevention and treatment of disease is propelling the revenue growth of the segment.
North America accounted for largest revenue share in 2020. Investment in healthcare sector keeps on increasing substantially every year to improve basic healthcare and modernize the whole sector. Such heavy investment has focused on fighting major diseases, authorized by the invention of valid and cost-effective drug development for side effect reduction and treatment, along with enhanced vector control.

Buy your Exclusive copy [Make Payment ]@ https://www.emergenresearch.com/select-license/70

Emergen Research has segmented the global in-vitro diagnostics market on the basis of product, devices, application, technique, end-use, and region:

Product Outlook (Revenue, USD Billion; 2018–2028)
- Reagents & Kits
- Instruments
  - Fully Automated Instruments
  - Semi-Automated Instruments
- Data Management Software
- Services
Devices Outlook (Revenue, USD Billion; 2018–2028)
- Reusable IVD Devices
- Disposable IVD Devices
Application Outlook (Revenue, USD Billion; 2018–2028)
- Cancer
- Infectious Diseases
- Diabetes
- Gastrointestinal Disease
- Autoimmune Diseases
- Cardiac Disease
- Drug Testing /Pharmacogenomics
- HIV/AIDS
- Nephrological Disease
- Others
Technique Outlook (Revenue, USD Billion; 2018–2028)
- Immunoassay
  - Enzyme-Linked Immunosorbent Assay
    - Chemiluminescenc e Immunoassays
    - Fluorescence Immunoassays
    - Colorimetric Immunoassays
  - Radioimmunoassay
  - Rapid Test
  - Western Blottin
  - Enzyme-Linked Immunospot Assays
- Clinical Chemistry
  - Basic Metabolic Panel
  - Electrolyte Panel
  - Liver Panel
  - Lipid Profile
  - Renal Profile
  - Thyroid Function Panel
  - Specialty Chemical Tests
- Molecular Diagnostics
  - Polymerase Chain Reaction
  - Isothermal Nucleic Acid Amplification Technology
  - Microarray
  - Hybridization
  - DNA Sequencing & Next-Generation Sequencing
  - Other Molecular Diagnostics Technologies
- Microbiology
- Hematology
- Coagulation and Hemostasis
- Urinalysis
- Other IVD Technologies
End-use Outlook (Revenue, USD Billion; 2018–2028)
- Hospitals & Clinics
- Diagnostic Laboratories
- Homecare Settings
- Others

Have a look at Report Description and Table of Contents of Market Research Report@ https://www.emergenresearch.com/industry-report/in-vitro-diagnostics-market

Regional Outlook (Revenue, USD Billion; 2018–2028)
- North America
  - U.S.
  - Canada
  - Mexico
- Europe
  - Germany
  - U.K.
  - France
  - Spain
  - BENELUX
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - South Korea
  - Rest of APAC
- Latin America
  - Brazil
  - Rest of LATAM
- Middle East & Africa
  - Saudi Arabia
  - UAE
  - Israel
  - Rest Of MEA

Explore more reports offered by Emergen Research:

Newborn Screening Market Size, Share, Trends, By Technology (Tandem Mass Spectrometry, Pulse Oximetry, Enzyme Based Assay, DNA Assay, Electrophoresis), By Product (Instruments, Reagents, Assay Kits), By Application, Forecasts to 2027

Next-Generation Sequencing Market by Technology (Whole Exome, Whole Genome, Others), By Workflow (Sequencing, Pre-Sequencing, Others), By Application (Consumer Genomics, HLA Typing, Others) and By End-Use (Academic, Clinical, Others), Forecasts to 2027

Regenerative Medicine Market By Product (Tools, Therapeutics), By Therapeutic Category (Musculoskeletal, Dermatology, Immunology & Inflammation, Cardiovascular), and By Applications (Wound Care, Musculoskeletal Disorders, Ocular Disorders), Forecasts to 2027

Patient Engagement Solutions Market By Component (Software, Hardware), By Delivery (Online, Offline), By Therapeutic Area (Chronic diseases, Fitness), By Application (Social, Health, Home Healthcare, Financial Health) and By End-User (Payers, Providers, Individuals), Forecasts to 2027

Molecular Diagnostics Point of Care Market By Test Location (PoC, OTC), By Technology (PCR-based, Hybridization-based, Others), By Application (Oncology, Hematology, Others) and By End-Use (Decentralized Labs, Hospitals, Others), Forecasts to 2027

Prefilled Syringes Increased demand in therapeutics post-COVID-19

Patient Engagement Solutions Empowering patient’s active engagement in their care

FemTech: The Intersection of End-to-End Technological Solutions and Female Health

Tag: Artificial Intelligence

Symphony IndustrialAI Appoints Barry Johnson President of Digital Manufacturing

Technology Investments will Help Oncology Practices Succeed in Value-based Care

aMind Joins Argano to Build Quote-to-Cash Solutions that Make Businesses Run Better

Diabetes Devices Market Size Worth $44.6 Billion By 2028 | CAGR 6.6%: Grand View Research, Inc.

BOC Group Advances The Lean Enterprise Architecture Experience With ADOIT 13.0

Voltaiq partners with Veniam to provide global solution for transferring electrified vehicle battery data

Appriss, Inc. Announces Definitive Agreement to Sell Appriss Insights, LLC to Equifax, Inc. for $1.825 billion

Loyalty Management Market Size Worth $17.65 Billion By 2028: Grand View Research, Inc.

Chlorobenzene Market to Grow With Substantial Growth Rate in Coming Years Says P&S Intelligence

Global In-Vitro Diagnostics Market Size to Reach USD 118.44 Billion in 2028 | Increased Investment in Research & Development in Molecular Diagnostics and Development of New Product is Driving the Industry Demand, says Emergen Research

Latest Members

Who is online

Latest Hashtags